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Introduction
A growing body of evidence suggests that reactive oxygen
species (ROS) play a role in human cancer [1–3]. Free
radical derivatives of molecular oxygen (superoxide,
hydrogen peroxide, hydroxyl radical) are generated during
normal metabolism, and are increased following ethanol
consumption, cigarette smoking, and exposure to ionizing
radiation. The consumption of antioxidants in foods,
vitamin and mineral supplements, and the use of
nonsteroidal anti-inflammatory drugs (NSAIDs) lower ROS
levels [2]. Oxidative damage to DNA followed by mutation
and alterations in gene expression are the principal
mechanisms by which ROS contribute to carcinogenesis
[1,4]. Several enzyme systems counteract oxidative
damage, including catalase, glutathione peroxidases, and
the superoxide dismutase family. Superoxide dismutases
AFFTP = age at first full-term pregnancy; CBCS = Carolina Breast Cancer Study; CI = confidence interval; ICR = interaction contrast ratio;
MnSOD = manganese superoxide dismutase; NSAID = nonsteroidal anti-inflammatory drug; OR = odds ratio; PCR = polymerase chain reaction;
ROS = reactive oxygen species.
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Abstract
Introduction: A polymorphism in the manganese superoxide
dismutase (MnSOD) gene, Ala-9Val, has been examined in
association with breast cancer risk in several epidemiologic
studies. Results suggest that the Ala allele increases the risk of
breast cancer and modifies the effects of environmental
exposures that produce oxidative damage to DNA.
Methods: We examined the role of the MnSOD  Ala-9Val
polymorphism in a population-based case–control study of
invasive and in situ breast cancer in North Carolina. Genotypes
were evaluated for 2025 cases (760 African Americans and
1265 whites) and for 1812 controls (677 African Americans
and 1135 whites).
Results: The odds ratio for MnSOD  Ala/Ala versus any
MnSOD Val genotypes was not elevated in African Americans
(odds ratio = 0.9, 95% confidence interval = 0.7–1.2) or in
whites (odds ratio = 1.0, 95% confidence interval = 0.8–1.2).
Greater than additive joint effects were observed for the
Ala/Ala genotype and smoking, radiation to the chest, and
occupational exposure to ionizing radiation. Antagonism was
observed between the Ala/Ala genotype and the use of
nonsteroidal anti-inflammatory drugs.
Conclusions: The  MnSOD  genotype may contribute to an
increased risk of breast cancer in the presence of specific
environmental exposures. These results provide further
evidence for the importance of reactive oxygen species and of
oxidative DNA damage in the etiology of breast cancer.
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convert superoxide (O2
–) to peroxide (H2O2) and
molecular oxygen (O2). There are three superoxide
dismutase enzymes: cytosolic superoxide dismutase,
mitochondrial superoxide dismutase (manganese
superoxide dismutase [MnSOD]), and extracellular
superoxide dismutase [5].
The MnSOD gene on chromosome 6q25 encodes human
MnSOD (also known as SOD2). MnSOD is synthesized in
the cytoplasm as a precursor protein and is transported to
the mitochondria, where it is processed and assembled
into an active homotetramer. Studies of MnSOD protein
expression showed higher levels in non-neoplastic breast
epithelial cells compared with levels in invasive breast
cancer [6]. MnSOD overexpression in breast cancer cell
lines leads to upregulation of GAD153 (which is involved
in the repair of double strand breaks in DNA) and to a
variety of redox-sensitive transcription factors [7]. MnSOD
also induces expression of the matrix metalloproteinase
MMP-2, which helps to mediate cell migration and
adhesion to the extracellular matrix [8]. Several
investigators hypothesize that MnSOD may act as a tumor
suppressor gene in breast epithelial cells [6,7,9].
A common polymorphism exists in the human MnSOD
gene. This Ala-9Val polymorphism is a single nucleotide
substitution of C → T at nucleotide 47, changing the
encoded amino acid from Ala (GCT) to Val (GTT) [10,11].
The amino acid change occurs within the N-terminal
mitochondrial targeting sequence, a 24-amino acid signal
sequence that targets the MnSOD precursor protein for
transport into the mitochondria. Mitochondrial localization
of MnSOD is required to protect cells from ionizing
radiation and other forms of oxidative damage [12]. The
variant residue is nine amino acids upstream of the
cleavage site, hence the polymorphism designation
Ala-9Val. Computer models predicted that the Val allele
would encode a beta-sheet conformation of the MnSOD
precursor protein that exhibited impaired transport into the
mitochondria, while the alpha-helical structure of the Ala-
containing precursor would show correct transport [10].
Recent experiments by Sutton and colleagues [13]
confirmed that, in rat liver, the human Val-containing
MnSOD protein has difficulty crossing the mitochondrial
inner membrane, leading to decreased formation of active
MnSOD within the mitochondrial matrix. The MnSOD Ala-
containing protein showed normal transport and
generated 30–40% more active MnSOD protein than did
the Val form of the enzyme.
Several epidemiologic studies have examined the
association of the MnSOD Ala-9Val polymorphism and
cancer. The Ala allele was associated with an increased
risk of breast cancer in two populations [14,15] but not in
another population [16]. The Ala allele was associated
with an increased risk of prostate cancer [17] and of early-
onset colorectal cancer [18], while the Val allele was
associated with an increased risk of lung cancer [19] and
of bladder cancer [20]. Studies of the role of MnSOD in
noncancer outcomes also showed mixed results [21]. We
conducted genotyping for MnSOD Ala-9Val genotypes in
the Carolina Breast Cancer Study (CBCS), a population-
based case–control study of breast cancer in African
Americans and whites. We estimated odds ratios (ORs)
for the MnSOD genotype and joint effects with several
environmental exposures.
Materials and methods
Study design and participants.
The CBCS is a population-based case–control study of
breast cancer conducted in North Carolina [22].
Participants provided informed consent using forms
approved by the Institutional Review Board of the
University of North Carolina School of Medicine, in
compliance with the Helsinki Declaration. Breast cancer
cases were identified in cooperation with the North
Carolina Central Cancer Registry, and controls were
identified using Division of Motor Vehicles lists (for
women younger than age 65 years) and using Health
Care Financing Administration lists (for women aged
65 years or older). Details of recruitment of participants
and response rates have been published previously
[23,24].
A total of 1803 cases of invasive breast cancer (787
African Americans and 1016 whites) and 1564 controls
(718 African Americans and 846 whites) were enrolled
between 1993 and 2001, and a total of 508 cases of in
situ breast cancer (107 African Americans and 401
whites) and 458 controls (70 African Americans and 388
whites) were enrolled between 1996 and 2001. Controls
were frequency matched to in situ cases based on age
(± 5 years) and on race. In the invasive study, the
response rates were 76.0% for cases and 55.0% for
controls. In the in situ study, the response rates were
82.7% for cases and 65.2% for controls.
Home interviews were conducted to obtain blood samples
and information on breast cancer risk factors. Response
rates for blood draws that contained usable DNA
combining all phases of the study were 89% for cases
and 90% for controls. DNA samples were provided for a
total of 2045 cases (768 African Americans and 1277
whites) and for 1818 controls (681 African Americans and
1137 whites).
Laboratory methods
DNA was extracted from whole blood using an automated
ABI-DNA extractor (Applied Biosystems Nuclei Acid
Purification System; Applied Biosystems, Foster City, CA,
USA) in the University of North Carolina SPORE Tissue
Procurement Facility. Genotyping for the MnSOD Ala-9ValBreast Cancer Research    Vol 6 No 4 Millikan et al.
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polymorphism (accession number S77127) was conducted
using an ABI 7700 Sequence Detection System or the
‘Taqman’™ assay (Applied Biosystems). PCR primers and
probes were designed using Primer Express™ software
(Applied Biosystems). The assay design and conditions
were based on the allelic discrimination protocol from
Applied Biosystems.
The Ala (C) allele-specific probe was labeled on the 5′
end with the VIC reporter dye and contained the
nucleotide sequence 5′-CAAAGCCGGAGCC-3′, with
69.2% G–C content and a melting temperature of 65.1°C.
The Val (T) allele-specific probe was labeled on the 5′ end
with the FAM reporter dye and contained the nucleotide
sequence 5′-CCAAAACCGGAGCC-3′, with 64.3% G–C
content and a melting temperature of 65.5°C. Both probes
contained the minor groove binding nonfluorescing
quencher dye on the 3′ end. Forward and reverse primers
were used to amplify the region surrounding the
polymorphism. The nucleotide sequence for the forward
primer was 5′-GGCTGTGCTTCTCGTCTTCA-3′, and the
melting temperature was 59.2°C with 52.4% G–C
content. The nucleotide sequence for the reverse primer
was 5′-TTCTGCCTGGAGCCCAGAT-3′, and the melting
temperature was 59.3°C with 57.9% G–C content.
PCR reactions were performed in a 15.0 µl reaction volume
using the hot-start format. The reaction components were
as follows: 1 × Taqman Universal PCR Master Mix,
900 nM each primer, 250 nM Ala (VIC), 150 nM Val (FAM)
probe, and 15.0 ng genomic DNA. PCR reactions were
run on a Perkin Elmer GenAmp® 9700 thermocycler
(Perkin Elmer, Boston, MA, USA) using the 9600 mode
under the following conditions: 50°C for 2 min
(AmpErase® UNG activation), 95°C for 10 min
(AmpliTaq® Gold activation), followed by 35 cycles of
95°C for 15 s (denature) and 57°C for 1 min
(anneal/extend). Synthetic oligonucleotides of 73 base
pairs corresponding to the MnSOD-9Val and MnSOD-9Ala
alleles were included as positive controls in each plate.
Samples that could not be scored were repeated.
MnSOD genotype data were obtained on a total of 3837
participants (2025 cases and 1812 controls). A total of
26 samples were not readable due to poor PCR
amplification. Genotyping was repeated on a random 10%
sample and results were identical to the original run.
Due to failure to observe Hardy–Weinberg equilibrium in a
portion of the samples (see Results), the accuracy of the
Taqman™ genotyping protocol was verified in three ways.
First, genotyping was repeated on 20% of samples
(n = 772) using the PCR-restriction fragment length
polymorphism assay developed by Ambrosone and
colleagues [14]. Five samples showed different results in
the two assays (99.9% agreement). The five samples were
repeated using the Taqman™ assay, and the results were
identical to the original Taqman™ results. Only the
Taqman™ results were therefore used in subsequent
statistical analysis.
For the second verification method, 15 DNA samples from
the Coriell Cell Repository (Camden, NJ, USA) were geno-
typed using the Taqman™ assay. The results corres-
ponded to the direct DNA sequencing results provided by
the NCI SNP500 project (http://SNP500cancer.nci.nih.gov).
Finally, we verified our Taqman genotyping procedure
using direct DNA sequencing. Five DNA samples for each
MnSOD  genotype (Ala/Ala, Ala/Val and Val/Val) were
amplified, were tagged with M13 forward and reverse
universal primers, and were analyzed on the ABI 3730
DNA Analyzer using the ABI Prism™ BigDye™ Version 1.1
Terminator Cycle Sequencing Ready Reaction Kit with
AmpliTaq®  DNA Polymerase, FS (Applied Biosystems)
(primer sequences and reaction conditions provided upon
request). All direct DNA sequencing results corresponded
to the previous genotyping results.
Statistical analysis
Differences in MnSOD allele frequencies between cases
and controls were determined using a chi-square test.
Departures from Hardy–Weinberg equilibrium were deter-
mined by comparing the observed genotype frequencies
with expected genotype frequencies calculated using
observed allele frequencies. Since deviations from
Hardy–Weinberg equilibrium were observed (see
Results), genotype frequencies in cases and controls
were compared using the Cochrane–Armitage test for
trend with a two-sided P value [25].
Age was based on age at diagnosis in cases or age at
selection in controls. Race was classified according to
self-report. Less than 2% of participants reported Native
American or other race, and these were classified as
whites. The stage at diagnosis in cases was classified
according to the American Joint Committee on Cancer
system based on review of medical records; data was
missing for 107 cases. Additional covariates included
family history (one or more first-degree relatives with
breast cancer), menopausal status, duration of active
cigarette smoking (years), any use of oral contraceptives,
any use of hormone replacement therapy (postmeno-
pausal women), a composite of age at first full-term
pregnancy (AFFTP) and parity (nulliparous, parity = 1 and
AFFTP <26 years, parity = 1 and AFFTP ≥26 years, parity
≥2 and AFFTP <26 years, and parity ≥2/AFFTP
≥26 years), age at menarche (continuous), lactation (ever,
never), and alcohol use (ever, never). Body mass index
(kg/m2) and waist–hip ratio were calculated using
measurements taken at the time of interview and were
included as continuous variables.High-dose radiation exposure to the chest was estimated
by asking about medical procedures, including coronary
catheterization, coronary angioplasty, and treatment of the
upper body with radiation (excluding treatment or
diagnosis for breast cancer). Occupational exposure was
based upon a history of working for 6 months or longer at
occupations with potential exposure to ionizing radiation
(nurses, medical doctors, X-ray technicians and laboratory
technicians) as described previously [26].
Participants were asked about any use of vitamin supple-
ments for the previous 5 years, including multivitamins,
vitamin A, vitamin C, vitamin E, and beta-carotene and
calcium, as detailed previously [27].
The use of NSAIDs was determined by asking participants
in phase 2 of the invasive study and the carcinoma in situ
study about use of a variety of medications using color
charts, as described previously [28]. Both prescription
NSAIDs and nonprescription items, such as aspirin and
acetaminophen, were included. Women who used
NSAIDs for less than 3 months or who reported sporadic
use (≤7 days per month) were classified as ‘occasional
users’. Women who used NSAIDs at least 8 days a month
for 3 months or more were classified into two groups:
those who used NSAIDs for less than 3 years’ total
duration were designated ‘short-term users’, while those
who used NSAIDs for 3 years or longer were ‘long-term
users’.
Participants were asked about their usual servings per
week of fruits and vegetables; a food frequency question-
naire or other comprehensive dietary history was not
obtained. For this analysis, participants were classified
according to the median consumption of fruits and
vegetables in controls during summer months.
The ORs for breast cancer were calculated using
unconditional logistic regression as implemented in the
SAS software program (version 8.1; SAS Institute, Cary,
NC, USA). Offset terms  were incorporated into models
using the SAS procedure, PROC GENMOD, to account
for the sampling probabilities used to define eligible cases
and controls [29]. Potential confounding was evaluated by
selecting covariates for final models that resulted in a
change of 10% or more for the beta coefficients for the
MnSOD genotype or the relevant environmental exposure.
Interaction was evaluated on the multiplicative scale by
comparing models with the main effects for the MnSOD
genotype and environmental factors with models
containing the main effects and interaction terms using a
likelihood ratio test. P < 0.10 for likelihood ratio tests was
considered statistically significant. Joint effects of the
MnSOD genotype and environmental factors were
estimated on an additive scale using a common referent
group [30]. Interaction contrast ratios (ICRs) and 95%
confidence intervals (CIs) were calculated in the SAS
software program as described by Lundberg and
colleagues [31]. The ICR is a measure of departure from
additive joint effects: ICR >0 implies greater than additive
effects (positive interaction on an additive scale or
synergy), ICR = 0 implies additive effects (no interaction),
and ICR <0 implies less than additive effects
(antagonism) [30]. For the present study, we consider
ICR ≥0.5 as evidence for a positive interaction on an
additive scale. To estimate ORs for vitamin and mineral
supplements, a common referent group of never users
was employed as described previously [27].
Joint effects using an additive scale are presented for
each exposure and MnSOD  genotype. Stratified results
using a multiplicative scale (two different referent groups)
are also presented for NSAID use and the MnSOD
genotype to assist in data interpretation.
Results
The characteristics of study participants and the response
rates [24], as well as ORs for breast cancer and vitamin
use, for smoking, for alcohol consumption, for exposure to
ionizing radiation, for hormone use, and for NSAIDs have
been previously published for the CBCS [26–28,32–35].
Briefly, modest inverse associations were observed for
use of multivitamins, vitamin C, and vitamin E [27]. Weak
positive associations were observed for smoking for
longer than 20 years [32], for alcohol consumption [33],
for high-dose radiation to the chest, and for occupational
exposure to ionizing radiation [26]. No association was
observed for hormone replacement therapy [34], and a
weak positive association was found among younger
women for the use of oral contraceptives [35]. An inverse
association was observed for the use of NSAIDs [28]. No
associations were found for summer or winter fruit and
vegetable intake, and results have not been previously
published for these variables.
Genotype and allele frequencies for MnSOD are
presented in Table 1 for both African American and white
study participants. The MnSOD-9Val allele was slightly
more common among African American controls
compared with white controls. The Val allele and the
Val/Val genotype frequencies were higher among African
American cases compared with controls, but the
differences were not statistically significant. MnSOD allele
and genotype frequencies were similar in cases compared
with controls among whites. The MnSOD genotype
frequencies did not differ according to stage at diagnosis
of breast cancer in African American or white cases (data
not shown).
The frequency of the Ala allele in white controls was within
the previously reported range for Europeans and American
Available online http://breast-cancer-research.com/content/6/4/R264
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equilibrium showed a borderline, statistically significant
departure from equilibrium distributions in African American
controls (P = 0.08) and a significant departure in white
cases (P = 0.005). In white cases, we observed an excess
of Val/Ala heterozygotes (681 observed versus 631
expected). In African American controls, there was also an
excess of heterozygotes (357 observed versus 335
expected). There was a nonsignificant excess of Val/Ala
heterozygotes in African American cases (P = 0.67) and
white controls (P = 0.26). In order to verify our Taqman™
genotyping results, we repeated MnSOD genotyping on
772 study participants using a PCR-restriction fragment
length polymorphism assay (as described in Materials and
methods); the results showed excellent agreement. In
most previous studies, MnSOD genotypes appear to be in
Hardy–Weinberg equilibrium, but these studies have not
included populations with large numbers of African
Americans.
The ORs for breast cancer and MnSOD genotypes in
African Americans and whites are presented in Table 1.
The ORs were close to the null value, with a slight inverse
association in African Americans and a slight positive
association in whites for Ala-containing genotypes
compared with Val/Val. The OR for MnSOD Ala/Ala versus
any MnSOD Val combining African American and white
study participants was 1.0 (95% CI = 0.8–1.1), and the
OR was similar for cases of carcinoma in situ versus
controls (OR = 0.8, 95% CI = 0.6–1.1) and for invasive
cancer cases versus controls (OR = 1.0, 95% CI =
0.9–1.2).
Breast Cancer Research    Vol 6 No 4 Millikan et al.
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Table 1
Manganese superoxide dismutase (MnSOD) genotype and allele frequencies and odds ratios for breast cancer in African
Americans and whites
Odds ratio 
MnSOD genotype and allele Cases Controls (95% confidence interval)a
African Americans n = 760 n = 677
Genotype frequenciesb
Val/Val 259 (34%) 196 (29%) Reference
Val/Ala 372 (49%) 357 (53%) 0.8 (0.6–1.0)
Ala/Ala 129 (17%) 124 (18%) 0.8 (0.6–1.1)
Cochran–Armitage trend test, P = 0.08
Val/Val or Val/Ala 631 (83%) 553 (82%) Reference
Ala/Ala 129 (17%) 124 (18%) 0.9 (0.7–1.2)
Allele frequenciesc
Val 0.59 (0.56–0.61) 0.55 (0.53–0.58)
Ala 0.41 (0.39–0.44) 0.45 (0.42–0.47)
Chi-square test, P = 0.08
Whites n = 1265 n = 1135
Genotype frequenciesb
Val/Val 273 (21%) 266 (23%) Reference
Val/Ala 681 (54%) 586 (52%) 1.2 (0.9–1.4)
Ala/Ala 311 (25%) 283 (25%) 1.1 (0.8–1.4)
Val/Val or Val/Ala 954 (75%) 852 (75%) Reference
Ala/Ala 311 (25%) 283 (25%) 1.0 (0.8–1.2)
Cochran–Armitage trend test, P = 0.59
Allele frequenciesc
Val 0.49 (0.47–0.51) 0.49 (0.47–0.51)
Ala 0.51 (0.50–0.55) 0.51 (0.49–0.53)
Chi-square test, P = 0.60
a Adjusted for offsets and age. b Data presented as n (%). c Data presented as frequency (95% confidence interval).The ORs for MnSOD stratified on menopausal status are
presented in Table 2. Values close to the null were
observed in each group. The ORs did not differ among in
situ or invasive breast cancer cases versus controls, and
they did not change after adjustment for known breast
cancer risk factors or any of the covariates presented in
Materials and methods (data not shown).
The ORs estimating the joint effects of the MnSOD
genotype and several environmental exposures are
presented in Table 3. The ORs for combinations of
MnSOD genotype and vitamin use, for alcohol use, and
for use of oral contraceptives were close to the null value,
and the ICRs were close to zero. The ORs were elevated
for combinations of MnSOD Ala/Ala genotype and for
smoking duration longer than 20 years, for high-dose
radiation to the chest, and for occupational exposure to
ionizing radiation. The ICRs suggested positive interaction
on an additive scale for each of these exposures and the
MnSOD Ala/Ala genotype.
A slight inverse association was observed for the combina-
tion of the MnSOD Ala/Ala genotype and hormone
replacement therapy, but the ICR was close to zero.
P values for likelihood ratio tests were less than 0.10 only
for the interaction of the MnSOD genotype and high-dose
radiation to the chest (P = 0.009). Results were similar in
African Americans and whites, and in premenopausal
women and postmenopausal women (data not shown).
ICRs were close to zero for the joint effects of summer
vegetable consumption and the MnSOD genotype (data
not shown).
The ORs for the joint effects of the MnSOD genotype and
NSAID use are presented in Table 4 for participants in
phase 2 of the invasive study and in the carcinoma in situ
study. ORs for combinations of the MnSOD genotype and
NSAID use are presented on a multiplicative scale and on
an additive scale. On a multiplicative scale, a strong
inverse association of NSAID use and breast cancer was
observed among participants with any MnSOD Val
genotype, but not the MnSOD  Ala/Ala genotype. The
P value for the likelihood ratio test was 0.09.
Joint effects were calculated on an additive scale using a
common referent group of any MnSOD Val genotype and
never using NSAIDs. ICRs >0 were observed for each
category of NSAID use and the MnSOD Ala/Ala genotype.
The ICR for ever using NSAIDs (occasional + short term +
long term) and the MnSOD Ala/Ala genotype was 0.5
(95% CI = 0.1–0.9). Since the ORs for the MnSOD
Ala/Ala genotype and NSAID use alone are both less than
1.0, ICR >0 for the combination of both exposures is
consistent with antagonism between NSAID use and the
MnSOD Ala/Ala genotype [30]. The antagonistic effects of
NSAID use and MnSOD genotype can be seen more
clearly on a multiplicative scale (Table 4), where the
protective effect of NSAID use was abolished among
participants with the MnSOD Ala/Ala genotype.
To compare our results with the two previous studies of
MnSOD genotypes and breast cancer, we calculated the
ORs for the MnSOD genotype and environmental factors
using the methods of Ambrosone and colleagues [14] and
Mitrunen and colleagues [15].
Available online http://breast-cancer-research.com/content/6/4/R264
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Table 2
Odds ratios for manganese superoxide dismutase (MnSOD) genotypes and breast cancer, according to menopausal status
MnSOD genotype Cases Controls Odds ratio (95% confidence interval)a
Premenopausal n = 904 n = 783
Val/Val 224 187 Reference
Val/Ala 479 417 1.0 (0.8–1.2)
Ala/Ala 201 179 1.0 (0.7–1.3)
Val/Val or Val/Ala 703 604 Reference
Ala/Ala 201 179 1.0 (0.8–1.2)
Postmenopausal n = 1121 n = 1029
Val/Val 308 275 Reference
Val/Ala 574 526 1.0 (0.8–1.2)
Ala/Ala 239 228 0.9 (0.7–1.2)
Val/Val or Val/Ala 882 801 Reference
Ala/Ala 239 228 0.9 (0.8–1.2)
a Adjusted for offsets, age and race.Ambrosone and colleagues [14] calculated ORs for the
MnSOD genotype after stratifying on environmental
exposures, using a separate referent group of the MnSOD
Val/Val genotype within each stratum. ORs were calculated
for the MnSOD genotype across strata of fruit and
vegetable intake and antioxidant use in premenopausal
women and postmenopausal women. In the present study,
ORs for the MnSOD genotype varied only slightly
Breast Cancer Research    Vol 6 No 4 Millikan et al.
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Table 3
Joint effects of the manganese superoxide dismutase (MnSOD) genotype and environmental risk factors on breast cancer
Val/Val or Val/Ala MnSOD genotype Ala/Ala MnSOD genotype
Cases/controls Odds ratio (95% CI) Cases/controls Odds ratio (95% CI) ICR (95% CI)
Vitamin usea
No vitamin use 626/543 Referent 148/143 0.9 (0.7–1.2)
Any vitamin use 959/862 0.9 (0.8–1.1) 292/264 0.9 (0.7–1.1) 0.1 (–0.2, 0.4)
Multivitamin use 791/695 1.0 (0.8–1.1) 235/200 0.9 (0.7–1.2) 0.1 (–0.2, 0.4)
Vitamin A 58/48 1.1 (0.7–1.7) 17/16 0.9 (0.4–1.9) –0.1 (–1.0, 0.7)
Vitamin C 405/363 1.0 (0.8–1.2) 129/103 1.1 (0.8–1.5) 0.3 (–0.1, 0.7)
Vitamin E 401/325 1.1 (0.9–1.3) 123/101 1.1 (0.8–1.5) 0.1 (–0.3, 0.6)
Beta-carotene 59/58 1.0 (0.7–1.6) 17/15 1.1 (0.5–2.4) 0.2 (–0.8, 1.1)
Calcium supplements 413/412 0.8 (0.7–1.0) 137/123 0.9 (0.7–1.3) 0.2 (–0.2, 0.6)
Smokingb
No active or passive 311/268 Referent 87/87 0.8 (0.6–1.2)
Passive only 540/478 1.0 (0.8–1.3) 143/144 1.0 (0.7–1.3)
Duration of active smoking
≤ 10 years 186/180 0.9 (0.7–1.3) 59/56 0.9 (0.6–1.3)
> 10 years to 20 years 175/166 1.0 (0.8–1.4) 52/49 0.8 (0.6–1.4)
> 20 years 366/309 1.2 (0.9–1.5) 96/71 1.5 (1.0–2.2) 0.5 (–0.1, 1.0)
Alcohol consumptionc
No 507/454 Referent 122/139 0.7 (0.6–1.0)
Yes 1076/949 1.0 (0.8–1.2) 318/268 1.0 (0.8–1.3) 0.3 (0.0, 0.6)
High-dose radiation to chesta
No 1468/1299 Referent 395/387 0.9  (0.8–1.1)
Yes 116/106 1.1 (0.8–1.4) 45/20 2.3 (1.3–4.1) 1.3 (0.0, 2.7)
Occupational exposure to ionizing radiationa
No 1497/1334 Referent 413/391 0.9 (0.8–1.1)
Yes 88/71 1.1 (0.8–1.6) 27/16 1.6 (0.8–3.1) 0.6 (–0.5, 1.7)
Oral contraceptives (regular use)a
No 561/511 Referent 136/146 0.9 (0.6–1.1)
Yes 1016/885 1.1 (0.9–1.4) 304/258 1.1 (0.9–1.4) 0.1 (–0.2, 0.5)
Hormone replacement therapy (postmenopausal women, regular use)a
No 436/375 Referent 117/106 1.0 (0.7–1.3)
Yes 446/426 0.8 (0.7–1.0) 122/122 0.7 (0.5–1.0) –0.1 (–0.5, 0.3)
CI, confidence interval; ICR, interaction contrast ratio. a Adjusted for offsets, age, race, family history, age at menarche, age at first full-term
pregnancy (AFFTP)/parity composite, smoking duration, and alcohol use. b Adjusted for offsets, age, race, family history, age at menarche,
AFFTP/parity composite, and alcohol use. c Adjusted for offsets, age, race, family history, age at menarche, AFFTP/parity composite, and smoking
duration.according to fruit and vegetable intake, and vitamin use,
and did not differ in premenopausal versus postmeno-
pausal women. The greatest difference noted was an
adjusted OR of 1.1 (95% CI = 0.8–1.4) for the MnSOD
Ala/Ala genotype versus any MnSOD  Val genotype
among participants with low summer vegetable intake,
compared with an OR of 0.9 (95% CI = 0.7–1.1) for
participants with high vegetable intake.
Mitrunen and colleagues [15] calculated the OR for
MnSOD genotypes (Ala/Ala versus Val/Val) after stratify-
ing on alcohol use, on smoking (ever/never) and use of
antioxidants, on oral contraceptives, and on hormone
replacement therapy. In the present study, adjusted ORs
for the MnSOD Ala/Ala genotype versus the MnSOD
Val/Val genotype were 1.1 (95% CI = 0.8–1.4) among
ever smokers and 0.8 (95% CI = 0.6–1.1) among never
smokers, and were 1.0 (95% CI = 0.8–1.3) among ever
drinkers and 0.8 (95% CI = 0.6–1.1) among never
drinkers. ORs for the MnSOD genotype were close to the
null value across the strata of the remaining covariates.
Discussion
Using data from a population-based case–control study of
invasive and in situ breast cancer in North Carolina, we
did not observe an association between the MnSOD
genotype and breast cancer (ignoring environmental
factors) in African American or white women, nor among
premenopausal or postmenopausal women. Ambrosone
and colleagues [14] reported a positive association for the
MnSOD Ala/Ala genotype and breast cancer in New York
state that was stronger in premenopausal women than in
postmenopausal women. Mitrunen and colleagues [15]
reported a weak positive association in women from
Finland that was similar in premenopausal and postmeno-
pausal women, while Egan and colleagues [16] observed
no association in premenopausal or postmenopausal
women from Massachusetts and New Hampshire.
The number of participants in the CBCS was larger than
in previous studies. The ORs for genotypes tend to
converge towards the null as the sample size increases in
association studies [36–38], and the phenomenon has
been seen previously for several loci in breast cancer [39].
We did not observe strong joint effects for the MnSOD
genotype and vitamin use or summer vegetable and fruit
consumption. Ambrosone and colleagues [14] reported
elevated ORs for the MnSOD Ala/Ala genotype in women
with low consumption of fruits and vegetables and dietary
sources of carotenoids, ascorbic acid, and alpha-
tocopherol. Egan and colleagues [16] did not observe
strong differences in the ORs for MnSOD stratified
according to fruit and vegetable intake. Mitrunen and
colleagues [15] reported that the OR for the MnSOD
genotype was stronger in persons who took vitamin A,
vitamin C, and vitamin E supplements. Fruit and vegetable
intake and dietary intake of vitamin A, vitamin C, and
vitamin E in the studies of Ambrosone and colleagues [14]
and of Egan and colleagues [16] were estimated using
detailed food frequency questionnaires. Mitrunen and
colleagues [15] did not collect information on dietary
intake of fruits and vegetables, and in the present study
only a few basic questions were asked about fruit and
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Table 4
Odds ratios for non-steroidal anti-inflammatory drug (NSAID) use stratified on the manganese superoxide dismutase (MnSOD)
genotype (multiplicative scale) and joint effects (additive scale) (phase 2 invasive and CIS studies only)
Val/Val or Val/Ala MnSOD genotype Ala/Ala MnSOD genotype
Use of NSAIDs Cases/controls Odds ratio (95% CI) a Cases/controls Odds ratio (95% CI) a ICR (95% CI)
Multiplicative scale
Never 105/48 Referent 19/16 Referent
Occasional 511/420 0.6 (0.4–0.8) 142/127 0.8 (0.4–1.9)
Short term 148/141 0.4 (0.3–0.7) 43/36 0.9 (0.4–2.4)
Long term 218/200 0.4 (0.3–0.7) 58/58 0.9 (0.4–2.1)
Additive scale
Never 105/48 Referent 19/16 0.5 (0.2–1.3)
Occasional 511/420 0.5 (0.4–0.8) 142/127 0.5 (0.3–0.7) 0.4 (–0.1, 0.9)
Short term 148/141 0.4 (0.3–0.7) 43/36 0.5 (0.3–1.0) 0.5 (–0.1, 1.1)
Long term 218/200 0.4 (0.3–0.7) 58/58 0.4 (0.2–0.7) 0.4 (–0.1, 0.9)
CI, confidence interval; ICR, interaction contrast ratio. a Adjusted for offsets, age, race, family history, age at menarche, age at first full-term
pregnancy/parity composite, smoking duration, alcohol use, lactation, menopausal status, oral contraceptive use, education, body mass index, and
waist–hip ratio.vegetable intake. The latter two studies thus had
insufficient power to fully investigate the joint effects of the
MnSOD genotype and intake of dietary antioxidants.
Modest joint effects for the MnSOD genotype and
smoking were observed in our study. Mitrunen and
colleagues [15] reported an elevated OR for the MnSOD
genotype among smokers, while Egan and colleagues
[16] reported a stronger association for the MnSOD
genotype in never smokers than in ever smokers. Neither
study addressed the duration of smoking.
We did not observe evidence for joint effects of the
MnSOD Ala/Ala genotype and use of alcohol, of oral
contraceptives, or of hormone replacement therapy.
Mitrunen and colleagues [15] reported elevated ORs for
the  MnSOD genotype in ever drinkers, in users of oral
contraceptives, and for postmenopausal estrogen use.
Egan and colleagues [16] reported a slightly elevated OR
for the MnSOD  genotype in women who used oral
contraceptives, but only a weak association among users
of hormone replacement therapy. We did not observe
strong joint effects for the MnSOD genotype and
exogenous hormone use in the present study. One
explanation may be that we did not observe strong main
effects (ignoring MnSOD genotypes) for oral contra-
ceptives [35] or for hormone replacement therapy [34] in
the CBCS. We also did not observe greater than additive
joint effects for the MnSOD  genotype and indices of
increased endogenous hormone exposure (early age at
menarche, nulliparity, late age at first pregnancy, late age
at menopause; data not shown). Relatively few persons
reported high levels of alcohol consumption in our study
population [33], decreasing the power to observe joint
effects with the MnSOD genotype.
We observed moderately elevated joint effects of
exposure to ionizing radiation and the MnSOD Ala/Ala
genotype. Previous studies of the MnSOD genotype and
breast cancer did not investigate interactions with
radiation exposure. Our results are consistent with
laboratory evidence that MnSOD expression plays a role
in adaptive responses to ionizing radiation [40]. Green
and colleagues [41] recently showed, however, that the
Ala-9Val polymorphism in MnSOD was not correlated with
sensitivity to radiotherapy in breast cancer patients. The
present results suggest that the MnSOD genotype could
influence the risk of breast cancer associated with low-
dose occupational and medical sources of ionizing
radiation, but additional epidemiologic studies are needed.
We observed evidence suggesting that the MnSOD
Ala/Ala genotype antagonizes a protective effect of
NSAID use and breast cancer. Several previous epidemio-
logic studies of breast cancer, as well as the CBCS,
demonstrated protective effects of NSAID use (for a
review, see [28]). In the CBCS, an inverse association
was observed for occasional and regular users, and for
users of prescription NSAIDs as well as nonprescription
NSAIDs. The effects were strongest among women with
the longest NSAID use [28]. Proposed mechanisms for
the protective effect of NSAID use include decreased
production of inflammatory cytokines, decreased cell
proliferation, and reduced production of ROS. Interactions
between NSAIDs and the MnSOD genotype suggest that
both factors operate on a common biochemical pathway
or series of pathways. Reduced ROS and decreased
oxidative damage may thus underlie the protective effect
of NSAID use and breast cancer. The gene–environment
interaction also provides evidence that the protective
effect of NSAIDs and breast cancer observed in the
present study and in previous epidemiologic studies may
be causal, and may not be due to confounding by lifestyle
or other factors.
Epidemiologic studies of the MnSOD Ala-9Val poly-
morphism are difficult to interpret in light of recent data
suggesting that the Val allele leads to impaired protein
transport and to reduced MnSOD activity, while the Ala
allele has normal activity [13]. Indeed, while studies of
breast cancer have consistently implicated the Ala allele in
increasing risk, studies of other health outcomes show
differing associations [13,17,18,21]. The transport studies
of Sutton and colleagues [13] were conducted in rat liver,
which may not be generalizable to human breast tissue or
other tissues. Since MnSOD removes the superoxide
anion, a potential source of DNA damage, one would
predict that that the MnSOD Val allele would lead to an
increased risk of cancer. On the other hand, MnSOD also
generates hydrogen peroxide that can be toxic if not
removed [13].
As suggested by Wang and colleagues [19], the effects
of the MnSOD polymorphism may depend upon the
tissue and tumor site, and may perhaps even depend on
the host species. The effects of the MnSOD genotype
also appear to depend upon environmental exposures
that increase or decrease the levels of ROS, and such
exposures may differ across populations. Finally, there
may be unidentified variants in linkage disequilibrium with
the  MnSOD-9Val allele that contribute to transport
and/or enzymatic activity. The complete story of the
MnSOD genotype is probably quite complex, a situation
that has proven true for many or most single-nucleotide
polymorphisms [42,43].
There are several weaknesses to our study. MnSOD
genotypes were not in Hardy–Weinberg equilibrium. One
possible explanation for this is laboratory error [44]. We
compared our genotyping results with a ‘gold standard’ of
direct DNA sequencing, and the results were identical.
Genotyping error can thus be practically excluded.
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A second weakness of our study is that we had limited
power to examine joint effects of the MnSOD  genotype
and dietary intake of antioxidants (due to lack of data) and
alcohol use (due to low levels of alcohol consumption in
our study population). Estimates of the joint effects of the
MnSOD genotype and exposure to ionizing radiation were
imprecise due to the small number of exposed participants.
Finally, the MnSOD Ala-9Val polymorphism may interact
with polymorphisms in other genes involved in modulating
levels of oxidative damage that were not measured in our
study. We did not observe evidence for joint effects of the
MnSOD genotype and polymorphisms in the glutathione
S-transferases  GSTM1, GSTT1, or GSTP1 (data not
shown). Genotyping for additional loci that could interact
with MnSOD was not conducted for study participants.
Conclusions
In a population-based case–control study of invasive and
in situ breast cancer in African American women and in
white women, we observed weak joint effects for the
MnSOD Ala/Ala genotype and several environmental
exposures. Our results are in agreement with previous
epidemiologic studies of breast cancer that showed no
main effects for the MnSOD genotype [16] and
interactions between the MnSOD Ala/Ala genotype and
environmental exposures that alter endogenous levels of
ROS species [14–16]. The present study adds to
previous knowledge by including exposure to ionizing
radiation as a potential environmental exposure that may
be mediated in part by MnSOD genotype. We also
identified a possible antagonistic interaction between
NSAID use and the MnSOD genotype.
Taken together, these four studies help to implicate ROS
as important biologic intermediates in the etiology of breast
cancer. However, the increased risk associated with the
MnSOD-9Ala allele is difficult to interpret given that the Val
allele (but not the Ala allele) is associated with reduced
MnSOD enzymatic activity in rat liver model systems [13].
As pointed out by St Clair and Kasarskis [21], more
functional studies of the MnSOD-9 polymorphism are
needed. Epidemiologic studies of MnSOD  will shed
additional light on the role of ROS in the etiology of breast
cancer and other diseases, and could help to understand
the mechanisms of NSAIDs and other medications that
reduce the risk of breast cancer.
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